Abstract

Biosynthesis of nanoparticles is the preferred route for the fabrication of biocompatible and cheaper drugs. In this study, the extract and major secondary metabolite from Helichrysum aureonitens, 3,5-dihydroxy-6,7,8-trimethoxyflavone, were used to synthesize silver and zinc oxide nanoparticles. Spectroscopic and microscopic techniques confirmed the formation of the nanoparticles. The flavone alone showed higher DPPH radical scavenging ability (IC50 = 487.1 μg mL−1) relative to the control, butylated hydroxytoluene. In addition, silver nanoparticles synthesized using the flavone had higher ferric reducing potential (Fe3+ to Fe2+) compared to the other test samples. The cytotoxic activity of the plant extract, the flavone, and their biosynthesized nanoparticles was also investigated using the MTT assay against the cancerous MCF-7 (breast adenocarcinoma) and A549 (human lung adenocarcinoma)), and non-cancerous HEK293 (human embryonic kidney) cell lines. The plant extract decreased the cell viability of A549 (IC50 = 68.6 μg mL−1) without being cytotoxic against HEK293, even at high concentrations. Silver nanoparticles significantly decreased cell viability of A549 and moderately decreased cell viability of MCF-7 but induced cell death of HEK293 even at low concentrations. This study provides a green synthesis route for silver and zinc oxide nanoparticles and confirms the therapeutic effectiveness of H. aureonitens, thereby validating its use in ethnomedicine.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.